New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
08:02 EDTLGNDLigand announces presentation of data from Phase 1 study
Ligand Pharmaceuticals announced that data from a Phase 1 study of the selective estrogen receptor modulator lasofoxifene were featured in a poster presentation today at ICE/ENDO 2014 in Chicago. The presentation provided data from a first-in-human clinical study of lasofoxifene that was performed by Pfizer and recently analyzed by Ligand demonstrating the potent and prolonged effect of a single dose to increase circulating testosterone and gonadotropin levels in healthy young men. Highlights of the presentation include: In an investigator-blinded, randomized, placebo-controlled, single-ascending dose study involving 36 healthy male volunteers, lasofoxifene was well-absorbed after oral administration with peak plasma concentrations reached approximately 6 to 9 hours post-dose and a long elimination half-life of approximately 106 hours; There were no serious adverse events and no clinically significant changes in safety laboratory, vital signs or ECG assessments; Single oral doses of lasofoxifene of 1, 3, 10, 30 and 100 mg increased levels of testosterone; doses of 30 and 100 mg increased levels of T by more than 80%; Levels of luteinizing hormone and follicle-stimulating hormone were also elevated with single oral doses of 30 and 100 mg; Levels of T, LH and FSH peaked between 3 and 7 days post-dose and elevations induced by higher doses were maintained through at least 28 days; T levels plateaued at the high normal range of 30-40 nmol/L between 7 and 28 days post-dose regardless of lasofoxifene dose or LH levels.
News For LGND From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 2, 2016
09:01 EDTLGNDLigand enters into OmniAb platform license pact with Tizona
Ligand Pharmaceuticals announced it has entered into a worldwide license agreement with Tizona Therapeutics, Inc. Under the license, Tizona will use the OmniRat, OmniMouse and OmniFlic platforms to generate fully human mono- and bispecific antibodies. Ligand will be eligible to receive annual platform access payments as well as patent filing fees, clinical milestone payments and royalties for each successful OmniAb antibody. Tizona will be responsible for all costs related to the program.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use